Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIGB-247
- Development stage
- Unknown
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CIGB-247 is a therapeutic cancer vaccine developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. It is an active immunotherapy composed of a recombinant human vascular endothelial growth factor (VEGF) variant as the antigen, formulated with a bacterial adjuvant. The vaccine is designed to break immune tolerance to self-VEGF, inducing a polyclonal antibody response that blocks the interaction between VEGF and its receptors, as well as stimulating a cellular immune response against VEGF-expressing tumor cells. This dual mechanism aims to inhibit tumor angiogenesis and metastasis. Clinical evaluation has progressed through Phase I (CENTAURO trial), demonstrating safety and immunogenicity in patients with advanced solid tumors, with further development targeting specific indications such as ovarian cancer and hepatocarcinoma.
- Other names
- VEGF vaccineCIGB 247CIGB247CIGB-247
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on CIGB-247.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIGB-247.